Interactive Updates in Solid Tumor Cancers: Lung Cancer Module

Needs Assessment

Lung cancer is the second most common cancer in both men and women, accounting for about 14% of all new cancer cases. The American Cancer Society estimates that in 2013, 228,190 new cases of lung cancer will be diagnosed, and 159,480 deaths will result from the disease. By far, lung cancer is the leading cause of cancer death in both men and women: each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, comprising of 85% of all cases. While NSCLC is not as aggressive as small-cell lung cancer, its subtypes have very poor prognosis once the disease has spread.1

Traditionally, first-line treatment of NSCLC includes platinum-based combination chemotherapy. In recent years, innovative diagnostic tools that enable greater detail in risk stratification and outcome prediction have become available. In turn, new, targeted therapies are being developed. As the translation of this data into therapeutic practices presents an educational and practice gap, the aim of this activity is to improve physician performance by providing oncologists, pulmonologists, and other healthcare professionals with relevant and timely information on the treatment of NSCLC.

1American Cancer Society. What are the key statistics about lung cancer? http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-key-statistics. January 2013.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and Carden Jennings Publishing. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Commercial Support

This activity is supported by an educational grant from Genentech Inc.

Off-Label/Investigational Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Medical College of Wisconsin, Carden Jennings Publishing or Genentech, Inc.

Before prescribing any medication, physicians should consult primary references and full prescribing information. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Target Audience

This program has been designed for a targeted audience of medical oncologists, radiation oncologists, surgical oncologists, pulmonologists, and other healthcare professionals specializing in the care of patients with non-small cell lung cancer.

Learning Objectives

Upon completion of the program, participants should be able to:

  1. Assess recent advances in the treatment of NSCLC
  2. Evaluate the role of EGFR mutation testing in NSCLC
  3. Discuss the emerging treatment options for advanced/metastatic disease
  4. Determine the therapeutic efficacy of stereotactic body radiation therapy
  5. Utilize iPad/eBook technology to access up-to-date and interactive textbook-based information on NSCLC
Additional information

CME Coordinator Contact Information

Name: 
Linda Caples
Phone Number: 
+1 (414) 955-4900
Email: 
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
04/07/2014
Course expires: 
04/10/2015
Cost:
$0.00

In 1984, Dr. Bunn was recruited to the University of Colorado Health Sciences Center as a Professor of Medicine in Medical Oncology and Head of the Division of Medical Oncology. In 1986 Dr. Bunn became the Director of the University of Colorado Comprehensive Cancer Center, a position he held until 2009. He is currently Distinguished Professor, University of Colorado and James Dudley endowed Professor at the University. Dr. Bunn has been President of ASCO, IASLC, and AACI, chairman of the FDA Oncology Drug Advisory Committee.

Dr. Bunn’s research interests focus on novel therapies for lung cancer. He has published more than 300 articles in peer-reviewed journals, 122 reviews and 90 book chapters on lung cancer. Dr. Bunn’s studies have set standards for the treatment of lung cancer, have identified issues of natural history and have identified biomarkers of prognosis and therapy selection. Dr. Bunn is the principal investigator on numerous national and local therapeutic trials and is also the principal investigator for the SPORE grant in lung cancer that is designed to conduct lung cancer translational research and Principal Investigator for the Lung Cancer Mutation Consortium.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Accreditation Period

Course opens: 
04/07/2014
Course expires: 
04/10/2015

Price

Cost:
$0.00
Please login or register to take this course.